Mirum Pharmaceuticals, Inc. (MIRM) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 5.28B USD. 52-week range 63.23 to 130.00 USD. Data as of 2026-10-09.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the ...